BioLine RX Ltd (BLRX.OQ)
* Qtrly loss per share $0.05 Source text for Eikon: Further company coverage:
* BiolineRx announces additional investment from BVF partners L.P.
* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.
BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors
* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors
* BioLine Rx Ltd qtrly loss per share $0.06 Source text for Eikon: Further company coverage:
* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML
* Biolinerx to initiate phase 3 study with bl-8040 as novel stem cell mobilization treatment following successful meeting with fda
* BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017 Source text:(http://bit.ly/2p0kRot) Further company coverage:
* BioLine rx ltd - priced underwritten public offering of about 29.4 million ADSs at public offering price of $0.85 per ads Source text for Eikon: Further company coverage:
* BioLine RX announces underwritten public offering of its american depositary shares